|
Affiliation |
Faculty of Medicine School of Nursing Life and basic nursing study course |
|
Title |
Professor |
|
External Link |
|
Sawada Hirotake
|
|
|
Degree 【 display / non-display 】
-
Doctor (Medicine) ( 2006.3 University of Miyazaki )
-
学士（医学） ( 1995.3 宮崎医科大学 )
Research Areas 【 display / non-display 】
-
Life Science / Clinical pharmacy
-
Life Science / Physiology
Papers 【 display / non-display 】
-
B-cell deficiency identified by newborn screening Reviewed
Matsumoto Takayuki, Nishimura Toyoki, Yamamoto Ayako, Sawada Hirotake, Moritake Hiroshi
JSIAD Journal 3 ( 1 ) 16 - 20 2024.2
Language：Japanese Publishing type：Research paper (scientific journal) Publisher：Japanese Society for Immunodeficiency and Autoinflammatory Diseases
Newborn screening（NBS）is carried out at public expense for approximately 20 diseases in Japan; however, each prefecture independently conducts additional NBS including several more diseases. Miyazaki Prefecture has optionally included inborn errors of immunity（IEIs）and lysosomal storage diseases since April 2020. We herein report a baby who suffered from B-cell deficiency（BCD）that was identified by NBS conducted in Miyazaki Prefecture. The baby had low levels of kappa-deleting recombination excision circles（KRECs）and was referred to our hospital. Several measurements of CD19-positive B cells in the peripheral blood consistently showed values <2%, leading to the diagnosis of BCD. Periodic immunoglobulin replacement successfully led to a healthy outcome without serious infection developing over a period of more than 17 months. This is the first case of BCD identified by NBS and that underwent prophylactic gamma globulin replacement in Japan. Severe combined immunodeficiency disease and BCD are IEIs known to cause severe sequelae, and patients sometimes die without a correct diagnosis being made; therefore, their early diagnosis and early treatment are extremely important. The inclusion of IEIs in NBS has proven to be cost-effective all over the world. In the future, it is expected that IEIs will be covered by NBS public funds in Japan as well.
-
Yamamura Yoshiko, Fukami Maki, Matsuyama Misayo, Sawada Hirotake
Clinical Pediatric Endocrinology 33 ( 1 ) 17 - 22 2024
Language：English Publishing type：Research paper (scientific journal) Publisher：The Japanese Society for Pediatric Endocrinology
-
Knowns and unknowns about congenital hypothyroidism: 2022 update Reviewed
Itonaga Tomoyo, Hasegawa Yukihiro, Higuchi Shinji, Satoh Mari, Sawada Hirotake, Shimura Kazuhiro, Takahashi Ikuko, Takubo Noriyuki, Nagasaki Keisuke
Clinical Pediatric Endocrinology 32 ( 1 ) 11 - 25 2023
Language：English Publishing type：Research paper (scientific journal) Publisher：The Japanese Society for Pediatric Endocrinology
Several excellent guidelines and expert opinions on congenital hypothyroidism (CH) are currently available. Nonetheless, these guidelines do not address several issues related to CH in detail. In this review, the authors chose the following seven clinical issues that they felt were especially deserving of closer scrutiny in the hope that drawing attention to them through discussion would help pediatric endocrinologists and promote further interest in the treatment of CH. 1. How high should the levothyroxine (L-T4) dose be for initial treatment of severe and permanent CH? 2. What is the optimal method for monitoring treatment of severe CH? 3. At what level does maternal iodine intake during pregnancy affect fetal and neonatal thyroid function? 4. Does serum thyroglobulin differ between patients with a dual oxidase 2 (<i>DUOX2</i>) variants and those with excess iodine? 5. Who qualifies for a genetic diagnosis? 6. What is the best index for distinguishing transient and permanent CH? 7. Is there any cancer risk associated with CH? The authors discussed these topics and jointly edited the manuscript to improve the understanding of CH and related issues.
-
Shikuri Y, Tanoue H, Imai H, Nakamura H, Yamaguchi F, Goto T, Kido Y, Tajika A, Sawada H, Ishida Y, Yoshinaga N
BMJ open 12 ( 4 ) e057286 2022.4
Language：English Publishing type：Research paper (scientific journal) Publisher：BMJ Open
Introduction Despite the recent global mental health movement of the transition from hospital-centred to integrated community-based services, comprehensive evidence of psychosocial interventions focusing on community-dwelling individuals with schizophrenia is still lacking. To overcome this gap in the current knowledge, we will conduct a systematic review and meta-analysis to assess the efficacy of all types of psychosocial interventions for community-dwelling (non-hospitalised) individuals with schizophrenia when compared with non-active control conditions (eg, treatment as usual). Methods and analysis This study protocol has been developed according to the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols guidelines. By March 2022, the following sources will have been searched, without restrictions for language or publication period: Embase, PubMed, PsycINFO, CINAHL, the Cochrane Central Register of Controlled Trials, ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform. We will also try to identify other potentially eligible studies by searching the reference lists of included studies, other relevant systematic reviews and grey literature. All relevant randomised controlled trials from both high-income and low-income to middle-income countries will be allowed. Two independent reviewers will conduct the selection/screening of studies, data extraction and methodological quality assessment of included studies. The primary outcomes are quality of life and psychiatric hospital admission. Standard pairwise meta-analyses with a random-effects model will be conducted. Subgroup and sensitivity analyses will be performed to assess the robustness of the findings. Risk of bias will be assessed with the Revised Cochrane Risk-of-Bias Tool for Randomised Trials. The Grades of Recommendation Assessment, Development and Evaluation approach will be used to assess the quality of evidence. Ethics and dissemination Ethics approval is not required for this study. The study findings will be disseminated through conference presentations as well as peer-reviewed publications. PROSPERO registration number CRD42021266187.
-
Misayo Matsuyama, Hirotake Sawada, Shinobu Inoue, Akira Hishinuma, Ryo Sekiya, Yuichiro Sato, Hiroshi Moritake
Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology 31 ( 3 ) 185 - 191 2022
Language：Japanese Publishing type：Research paper (scientific journal) Publisher：The Japanese Society for Pediatric Endocrinology
Thyroglobulin gene abnormalities cause thyroid dyshormonogenesis. A 6-yr-old boy of consanguineous parents presented with a large goiter and mild hypothyroidism (thyroid-stimulating hormone [TSH] 7.2 μIU/mL, free T3 [FT3] 3.4 pg/mL, free T4 [FT4] 0.6 ng/dL). Despite levothyroxine (LT4) administration and normal TSH levels, the goiter progressed slowly and increased rapidly in size at the onset of puberty. Thyroid scintigraphy revealed a remarkably high 123I uptake of 75.2%, with a serum thyroglobulin level of 13 ng/ml, which was disproportionately low for the goiter size. DNA sequencing revealed a novel homozygous missense variant, c.434G>A [p.Gly145Glu], in the thyroglobulin gene. Goiter growth was suppressed by increasing the LT4 dose. Thyroidectomy was performed at 17-yr-of-age. Thyroglobulin analysis of the thyroid tissue detected mutant thyroglobulin present in the endoplasmic reticulum, demonstrating that thyroglobulin transport from the endoplasmic reticulum to the Golgi apparatus was impaired by the Gly145Glu variant. During the clinical course, an elevated FT3/FT4 ratio was observed along with thyroid enlargement. A high FT3/FT4 ratio and goiter seemed to be compensatory responses to impaired hormone synthesis. Thyroglobulin defects with goiter should be treated with LT4, even if TSH levels are normal.
Books 【 display / non-display 】
-
歯科からの紹介患者の治療成果および医科歯科連携への期待について
澤田浩武（ Role： Sole author）
小児歯科臨床 2018.11
Language：Japanese
-
総説：小腸・胎盤におけるカルシウム吸収調節
澤田浩武（ Role： Sole author）
宮崎県医師会医学会誌 2018.2
Language：Japanese
-
新しい新生児マススクリーニングの課題
澤田浩武（ Role： Sole author）
日本遺伝看護学会誌 2018.2
Language：Japanese
MISC 【 display / non-display 】
-
【GPCR研究の最前線】カルシトニン受容体刺激ペプチド
澤田浩武,片渕剛,南野直人
内分泌・糖尿病科 22 ( 4 ) 445 - 450 2006.4
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media) Publisher：科学評論社
-
Boyden E., Campos-Xavier A., Kalamajski S., Cameron T., Suarez P., Tanackovic G., Andria G., Ballhausen D., Briggs M., Hartley C., Cohn D., Davidson H., Hall C., Ikegawa S., Jouk P., König R., Megarbané A., Nishimura G., Lachman R., Mortier G., Rimoin D., Rogers R., Rossi M., Sawada H., Scott R., Unger S., Valadares E., Bateman J., Warman M., Superti-Furga A., Bonafé L.
American Journal of Human Genetics 90 ( 1 ) 2012.1
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (bulletin of university, research institution) Publisher：American Journal of Human Genetics
-
第26回ヤングフェニックスサマーキャンプ
澤田浩武,栗林忠信
プラクティス 21 ( 5 ) 578 - 579 2004.9
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media) Publisher：医歯薬出版
Presentations 【 display / non-display 】
-
RARS2変異により橋小脳低形成6型を呈した日本人2家系
味原さや香 野々宮瑞紀 娼佐かおり 武者育麻 荒尾正人 齋藤恵 澤田浩武 村山圭 岡崎康司 大竹明
第61回日本先天代謝異常学会
Event date： 2019.10.24 - 2019.10.26
Language：Japanese Presentation type：Poster presentation
-
胎盤カルシウムイオンチヤネルTRPV6遺伝子異常による新生児一過性副甲状腺機能充進症
山下純英 澤田浩武 鈴木喜郎 水本洋 秦大資
第53回日本小児内分泌学会学術集会
Event date： 2019.9.26 - 2019.9.28
Language：Japanese Presentation type：Poster presentation
-
学校検尿での尿糖強陽性緊急受診システムの現状と問題点：九州沖縄地区における調査
山本幸代 香月きょう子 徳永剛 木下英一 長谷川宏 松本志郎 是松聖悟 澤田浩武 鮫島幸二 鹿島直子 吉田朝秀 宮里善次
第53回日本小児内分泌学会学術集会
Event date： 2019.9.26 - 2019.9.28
Language：Japanese Presentation type：Poster presentation
-
高チロシン血症１型の１例並びに移植後のニチシノン投与について
松本志郎 吉田敬伸 河崎達也 坂本理恵子 城戸淳 山本英和 澤田浩武 字藤山麻衣子 盛武浩 猪股裕紀洋 遠藤文夫 中村公俊
第60回日本先天代謝異常学会
Event date： 2018.11.8 - 2018.11.10
Language：Japanese Presentation type：Oral presentation (general)
-
横紋筋融解を契機に判明したcPT2欠損症の兄弟例
麻田智子 宇藤山麻衣子 松山美静代 盛武浩 瀧田浩武 原圭一 但馬剛
第60回日本先天代謝異常学会
Event date： 2018.11.8 - 2018.11.10
Language：Japanese Presentation type：Poster presentation
Grant-in-Aid for Scientific Research 【 display / non-display 】
-
新規疾患の新生児マススクリーニングに求められる実施体制の構築に関する研究
Grant number：23DA0801 2023.04 - 2026.03
厚生労働省 厚生科研 成育疾患克服等次世代育成基盤研究事業
Authorship：Coinvestigator(s)
-
舌色を活用した栄養状態自己管理システムの構築
Grant number：22K11088 2022.04 - 2026.03
日本学術振興会 科学研究費助成事業 基盤研究(C) 基盤研究(C)
竹山 ゆみ子, 永松 有紀, 澤田 浩武, 原口 直樹, 大川 百合子
Authorship：Coinvestigator(s)
-
舌の色構成を活用した高齢者の栄養評価指標の開発
Grant number：18K10574 2018.04 - 2023.03
日本学術振興会 科学研究費助成事業 基盤研究(C) 基盤研究(C)
竹山 ゆみ子, 永松 有紀, 澤田 浩武, 甲斐 由紀子
Authorship：Principal investigator
本研究の目的は、介護老人保健施設を利用している65歳以上の女性と地域在住の65歳以上の女性に対して、舌色撮影と血液生化学検査、身体計測、舌圧測定を実施し、高齢者に対する簡便で非侵襲的な栄養評価システム構築に向けた、「舌色」の栄養評価指標としての有用性を検証することである。現在、地域在住女性高齢者50名のデータ収集を行っている。対象者の平均年齢は73.84±5.25歳であり、前期高齢者70.28±3.14歳（29名）、後期高齢者78.81±3.14歳（21名）であった。舌圧と握力は相関したが、上腕筋面積や全身の骨格筋量とは相関しなかった。本研究はWorld Dysphagia Summitで発表した。介護老人保健施設の入所女性高齢者は、新型コロナウイルス感染症の影響で、データ収集できていない。そのため、前回収集した介護老人保健施設女性高齢者のデータと、今回の地域在住女性高齢者のデータの傾向を分析した。舌圧は、栄養状態を反映する血液検査値・身体計測値は有意差がみられたが、上腕筋面積とは有意な差はみられなかった。本研究の分析結果は、学会で発表予定である。
今後は、舌色についても前回収集した介護老人保健施設女性高齢者のデータと地域在住女性高齢者のデータの傾向を確認し、良好な舌色の色構成の特定にむけて検証する。 -
Effects of DHA in the brain on energy homeostasis in Mfsd2 KO mice
Grant number：16K09971 2016.04 - 2020.03
Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C) Grant-in-Aid for Scientific Research (C)
Sawada Hirotake
Authorship：Principal investigator
Behavioral analysis of Mfsd2 KO mice in free-living and 8-way radial maze tests revealed attention deficits, cognitive impairment, memory loss, poor concentration, and anxiety disorders. These disorders were thought to be caused by the lack of DHA in the brain. This suggests that lack of DHA in the brain may cause developmental delay and developmental problems in humans as well as mice. DHA in the brain is important for neurodevelopment in infancy and childhood.
Impaired balance in motor function was also seen in Mfsd2 KO mice, indicating cerebellar dysfunction. This implies that DHA in the brain is also important for motor function.
Histologically, brain atrophy of KO mice was detected. In addition, KO mice may also have olfactory abnormalities. -
Mfsd2遺伝子KOマウスを用いた、脳内ＤＨＡによるエネルギー代謝調節機構の解明
2016.04 - 2019.03
科学研究費補助金 基盤研究(C)
Authorship：Principal investigator
Mfsd2 (Major facilitator superfamily domain containing 2) はDHA(ドコサヘキサエン酸）のトランスポーターとして末梢から脳内へのDHA供給に重要な役割を果たし、脳内エネルギー代謝、神経発達、神経活動に重要な役割を果たしている。申請者のグループは、Mfsd2遺伝子ノックアウトマウス(KOマウス)を作出し、発育・発達・栄養・内分泌について評価してきた。本研究は、末梢のDHAが十分であるにもかかわらず、脳内のDHAが欠如するMfsd2 KOマウスの解析を通じて、脳内DHAがエネルギー代謝調節機構および食物選択行動調節機構にどのような影響を及ぼしているかを解明する。この研究は中枢を介した臓器間ネットワークにおける脳内DHAの役割について新たな知見を提供できるものと考えている。計画している具体的な研究項目は以下のとおりである。
① DHAとMfsd2 の発現・分布部位と成長に伴う発現量・分布量の検討
② Mfsd2 KOマウスの摂食行動およびエネルギー代謝特性
③ Mfsd2 KOマウスの代謝関連遺伝子発現